nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).

被引：6
|
作者：
Firdaus, Irfan
Waterhouse, David Michael
Gutierrez, Martin
Wainberg, Zev A.
George, Ben
Kelly, Karen
Bekaii-Saab, Tanios S.
Carrizosa, Daniel R.
Soliman, Hatem Hussein
Fraser, Cindy Duval
Ko, Amy
Pierce, Daniel W.
Manax, Victoria G.
Stergiopoulos, Sotirios G.
Hochster, Howard S.
机构：
[1] Oncol Hematol Care Inc, Sarah Cannon Res Inst, Cincinnati, OH USA
[2] OHC Oncol Hematol Care, Blue Ash, OH USA
[3] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[4] Ronald Regan UCLA Med Ctr, Los Angeles, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Levine Canc Inst, Charlotte, NC USA
[9] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[10] Celgene Corp, Summit, NJ USA
[11] Celgene Corp, Great Neck, NY USA
[12] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS475
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
  • [42] Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
    Park, J. Oh
    Li, C-P.
    Chang, H-M.
    Shan, Y. S.
    Bendell, J.
    Garlipp, B.
    Hatoum, H.
    Laquente Saez, B.
    Salminen, T.
    Oettle, H.
    Kocsis, J.
    Lopez, R.
    Dowden, S.
    Karthaus, M.
    Lu, B.
    McGovern, D.
    Banerjee, S.
    Tempero, M.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1313
  • [43] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts
    George, B.
    Kelly, K.
    Ko, A.
    Soliman, H.
    Trunova, N.
    Wainberg, Z.
    Waterhouse, D.
    O'Dwyer, P.
    Hochster, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    PANCREAS, 2020, 49 (04) : 574 - 578
  • [45] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [46] Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
    De Vita, Fernando
    Orditura, Michele
    Febbraro, Antonio
    Morgillo, Floriana
    Laterza, Maria Maddalena
    Fabozzl, Alesslo
    Giordano, Guido
    Savastano, Beatrice
    Petrillo, Angelica
    Ventriglia, Joie
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc)
    Davelaar, John
    Tighiouart, Mourad
    Hendifar, Andrew Eugene
    Osipov, Arsen
    Moshayedi, Natalie
    Placencio-Hickok, Veronica
    Bhowmick, Neil
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [48] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [49] Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P plus GEM) FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
    Kodama, Tomoko
    Nakazawa, Junichi
    Kawahira, Masahiro
    Ymasuji, Akihiro
    Iwashita, Yuji
    Hori, Takeshi
    Kawahira, Machiko
    Arima, Shiho
    Tubouchi, Hirohito
    Ido, Akio
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
12345